Welcome to all of our incoming interns - we can't wait to see you in Boston in a few short months!

Thrilled to have matched to Brigham and Women's Medicine Residents for internal medicine! Been quite a journey and can’t wait to see what the future holds. Thank you to David Geffen School of Medicine at UCLA for the best medical education I could have possibly imagined. Time to get a real winter coat! #dgsom2022 #match2022

Wealth of new data for PCSK9i over past 18 months: Safety/efficacy in high risk subgroups, plaque imaging in AMI, ongoing large trials, and future Rx to inhibit PCSK9 summarized in 1 comprehensive paper Danny McClintick, MD Robert Giugliano journals.lww.com/co-lipidology/…

See Danny McClintick, MD's poster, "Long-Term Efficacy of Evolocumab in Patients With and Without Multivessel Coronary Artery Disease", in 24 hrs in Sci & Tech Hall Zone 3, Board 3071 Michelle O'Donoghue Robert Giugliano Brigham and Women's Medicine Residents #AHA23

See Khaled Abdelrahman present his poster on Cardiometabolic Risk Factors and Non-Culprit Plaque Characteristics in Patients With STEMI in REAL-TIMI 63B, tomorrow at 3:00 in Sci & Tech Hall Zone 4, Board 4056 @kmabdlr @brianbergmark Brigham and Women's Medicine Residents #AHA23

Dr. Sachit Singal presents his work on Modes of In-Hospital Death in Patients With Cardiogenic Shock (CS): An Analysis From the Critical Care Cardiology Trials Network (CCCTN), in 24 hrs in 103C Critical Care Cardiology Trials Network Brigham and Women's Medicine Residents Sachit Singal, MD #AHA23

Benefit of long-term #evolocumab in FOURIER and FOURIER-OLE grows over time, providing large reductions in MACE for CAD patients both with and without multivessel disease #PCSK9 Michelle O'Donoghue Io 🤗 Danny McClintick, MD #AHA23

👉Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review ☝️PCSK9i represent a potent class of lipid-lowering therapies that are well tolerated and effective in a wide group of patients with high-risk atherosclerotic cardiovascular disease. ☝️Ongoing studies of

Evolocumab reduced the rate of major adverse CV events in patients with and without MVD and the benefit tended to occur earlier and was larger in patients with MVD. Read more on Evolocumab in patients with or without multivessel disease: bit.ly/3w1GAn0

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER dlvr.it/T2VM9c

Now out in JACC Journals and covered by TCTMD & American College of Cardiology, Danny McClintick, MD's paper showing benefit of long-term #evolocumab in FOURIER and FOURIER-OLE grows over time, providing large reductions in MACE for CAD pts both w/ & w/o multivessel disease jacc.org/doi/10.1016/j.…

Maddie Musselman wants to go to Paris. Same for her husband, Pat Woepse, who was diagnosed with cancer in September. A story about love, faith, water polo and the people you fight for. apnews.com/article/b09a23…

Coverage in @practiceupdate of @danmcclintick's paper on efficacy of #evolocumab in patients with and without multivessel coronary disease in FOURIER practiceupdate.com/content/long-t…

Tomorrow at 9:45 in Hall B4-5, Danny McClintick, MD presents his work on use of palliative care services in patients with cardiogenic shock Critical Care Cardiology Trials Network @Ebohula @DDBergMD #ACC24

Palliative care is consulted in ~1/3 of c-shock pts w/ fatal outcome in CICU, w/ wide variation by site. Palliative care consult was a/w ↑ likelihood of transition to CMO prior to death Danny McClintick, MD Critical Care Cardiology Trials Network @Ebohula @DDBergMD #ACC24

We are heartbroken by the passing of Patrick Woepse. A longtime water polo player winning championships at Mater Dei and UCLA he inspired the entire water polo world in his battle against a rare lung cancer. There was no bigger victory this past summer in Paris than when

Don't miss Danny McClintick, MD present his abstract on a polygenic score to identify risk of incident stroke and benefit from primary prevention statin therapy, tomorrow at 2pm in Zone 1, Moderated Digital Poster 2 #AHA24

A polygenic risk score can identify primary prevention patients at 4x higher risk of stroke. This increased risk appears to be offset by treatment with rosuvastatin. Danny McClintick, MD Nicholas Marston #AHA24